Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells

Guohua Wang; Yadong Wang; Weixing Feng; Xin Wang; Yang, Jack Y.; Yuming Zhao; Yue Wang; Yunlong Liu
January 2008
BMC Genomics;2008 Supplement 2, Vol. 9, Special section p1
Academic Journal
Background: Prostate cancer is one of the leading causes of cancer death in men. Androgen ablation, the most commonly-used therapy for progressive prostate cancer, is ineffective once the cancer cells become androgen-independent. The regulatory mechanisms that cause this transition (from androgen-dependent to androgen-independent) remain unknown. In this study, based on the microarray data comparing global gene expression patterns in the prostate tissue between androgen-dependent and -independent prostate cancer patients, we indentify a set of transcription factors and microRNAs that potentially cause such difference, using a model-based computational approach. Results: From 335 position weight matrices in the TRANSFAC database and 564 microRNAs in the microRNA registry, our model identify 5 transcription factors and 7 microRNAs to be potentially responsible for the level of androgen dependency. Of these transcription factors and microRNAs, the estimated function of all the 5 transcription factors are predicted to be inhibiting transcription in androgen-independent samples comparing with the dependent ones. Six out of 7 microRNAs, however, demonstrated stimulatory effects. We also find that the expression levels of three predicted transcription factors, including AP-1, STAT3 (signal transducers and activators of transcription 3), and DBP (albumin D-box) are significantly different between androgen-dependent and -independent patients. In addition, microRNA microarray data from other studies confirm that several predicted microRNAs, including miR-21, miR-135a, and miR-135b, demonstrate differential expression in prostate cancer cells, comparing with normal tissues.


Related Articles

  • Nrf1 and Nrf2 Transcription Factors Regulate Androgen Receptor Transactivation in Prostate Cancer Cells. Schultz, Michelle A.; Hagan, Sharika S.; Datta, Amrita; Zhang, Yiguo; Freeman, Michael L.; Sikka, Suresh C.; Abdel-Mageed, Asim B.; Mondal, Debasis // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Despite androgen deprivation therapy (ADT), persistent androgen receptor (AR) signaling enables outgrowth of castration resistant prostate cancer (CRPC). In prostate cancer (PCa) cells, ADT may enhance AR activity through induction of oxidative stress. Herein, we investigated the roles of Nrf1...

  • Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility. Hsiao, Jordy J.; Ng, Brandon H.; Smits, Melinda M.; Jiahui Wang; Jasavala, Rohini J.; Martinez, Harryl D.; Lee, Jinhee; Alston, Jhullian J.; Hiroaki Misonou; Trimmer, James S.; Wright, Michael E. // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Identifying cellular signaling pathways that become corrupted in the presence of androgens that increase the metastatic potential of organ-confined tumor cells is critical to devising strategies capable of attenuating the metastatic progression of hormone-naïve, organ-confined...

  • TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Gery, Sigal; Sawyers, Charles L.; Agus, David B.; Said, Jonathan W.; Koeffler, H. Phillip // Oncogene;7/18/2002, Vol. 21 Issue 31, p4739 

    Presents a study that identified an androgen regulated gene LNCaP expressed almost exclusively in the prostate that is identical to the recently described tomoregulin gene TMEFF2. Presence of TMEFF2 in normal human prostate as well as androgen-dependent prostate cancer cells; Role of the...

  • FUS/TLS Is a Co-Activator of Androgen Receptor in Prostate Cancer Cells. Haile, Simon; Lal, Aaron; Myung, Jae-Kyung; Sadar, Marianne D. // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Androgen receptor (AR) is a member of the nuclear receptor family of transcription factors. Upon binding to androgens, AR becomes transcriptionally active to regulate the expression of target genes that harbor androgen response elements (AREs) in their promoters and/or enhancers. AR is essential...

  • The Choice of the Filtering Method in Microarrays Affects the Inference Regarding Dosage Compensation of the Active X-Chromosome. Castagné, Raphaële; Rotival, Maxime; Zeller, Tanja; Wild, Philipp S.; Truong, Vinh; Trégouët, David-Alexandre; Munzel, Thomas; Ziegler, Andreas; Cambien, François; Blankenberg, Stefan; Tiret, Laurence // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Background: The hypothesis of dosage compensation of genes of the X chromosome, supported by previous microarray studies, was recently challenged by RNA-sequencing data. Itwas suggested thatmicroarray studies were biased toward an over-estimation of X-linked expression levels as a consequence of...

  • Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. Yonghua Yang; Huayan Hou; Haller, Edward M.; Nicosia, Santo V.; Wenlong Bai // EMBO Journal;3/9/2005, Vol. 24 Issue 5, p1021 

    Forkhead box class O (FOXO) proteins are transcription factors that function downstream of the PTEN tumor suppressor and directly control the expression of genes involved in apoptosis, cell cycle progression, and stress responses. In the present study, we show that FOXO1 interacts with four and...

  • Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Baron, Veronique; De Gregorio, Giorgia; Krones-Herzig, Anja; Virolle, Thierry; Calogero, Antonella; Urcis, Rafael; Mercola, Dan // Oncogene;7/3/2003, Vol. 22 Issue 27, p4194 

    Transcription factor early growth response-1 (Egr-1) is a crucial regulator of cell growth, differentiation and survival. Several observations suggest that Egr-1 is growth promoting in prostate cancer cells and that blocking its function may impede cancer progression. To test this hypothesis, we...

  • GLI1 Confers Profound Phenotypic Changes upon LNCaP Prostate Cancer Cells That Include the Acquisition of a Hormone Independent State. Nadendla, Sandeep K.; Hazan, Allon; Ward, Matt; Harper, Lisa J.; Moutasim, Karwan; Bianchi, Lucia S.; Naase, Mahmoud; Ghali, Lucy; Thomas, Gareth J.; Prowse, David M.; Philpott, Michael P.; Neill1, Graham W. // PLoS ONE;2011, Vol. 6 Issue 5, p1 

    The GLI (GLI1/GLI2) transcription factors have been implicated in the development and progression of prostate cancer although our understanding of how they actually contribute to the biology of these common tumours is limited. We observed that GLI reporter activity was higher in normal (PNT-2)...

  • Comparison of DGGE and immunohistochemistry in the detection of TP53 variants in a Brazilian sample of sporadic breast tumors. da Costa Aguiar, Vitor Rezende; de Freitas Cordeiro-Silva, Melissa; de Carvalho, Alex Assis; Louro, Iúri Drumond // Molecular Biology Reports;Jun2011, Vol. 38 Issue 5, p3351 

    The presence of TP53 gene mutations in breast cancer has been associated with worse prognosis. These mutations interfere with the ability of the p53 protein, a transcription factor, to regulate the expression of target genes. Unlike the wild-type protein, which is rapidly degraded in cells,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics